Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seiji Ueda

Showing results (1-10 of 124) with videos related to

Pageof 13
Sort By:
Hypertension Research : Official Journal of the Japanese Society of Hypertension|September 25, 2024
Correction: Urinary chloride-to-potassium ratio as a potential novel index for MR activity in patients with hypertensionHajime Nagasawa, Teruyuki Okuma, Seiji Ueda
Nihon Rinsho. Japanese Journal of Clinical Medicine|June 14, 2011
[Hyperfiltration]Yusuke Kaida, Seiji Ueda, Seiya Okuda
Hypertension Research : Official Journal of the Japanese Society of Hypertension|June 24, 2024
Urinary chloride-to-potassium ratio as a potential novel index for MR activity in patients with hypertensionHajime Nagasawa, Teruyuki Okuma, Seiji Ueda
Circulation Journal : Official Journal of the Japanese Circulation Society|February 5, 2014
Molecular mechanism underlying the renoprotective action of vitamin DYosuke Nakayama, Seiji Ueda, Seiya Okuda
Clinical and Experimental Nephrology|February 7, 2016
Accurate estimation of protein/creatinine ratio on urine sample in CKD patientsKensei Taguchi, Seiji Ueda, Kei Fukami
Current Pharmaceutical Design|September 28, 2007
Food-derived advanced glycation end products (AGEs): a novel therapeutic target for various disordersSho-ichi Yamagishi, Seiji Ueda, Seiya Okuda
Journal of Nephrology|March 30, 2010
New pathways to renal damage: role of ADMA in retarding renal disease progressionSeiji Ueda, Sho-Ichi Yamagishi, Seiya Okuda
Expert Opinion on Investigational Drugs|October 19, 2024
Dual blockade of endothelin A and angiotensin II type 1 receptors with sparsentan as a novel treatment strategy to alleviate IgA nephropathyHajime Nagasawa, Hitoshi Suzuki, Seiji Ueda, et al.
Current Pharmaceutical Design|May 14, 2008
Role of AGEs in diabetic nephropathyKei Fukami, Sho-Ichi Yamagishi, Seiji Ueda, et al.
Nihon Naika Gakkai Zasshi. the Journal of the Japanese Society of Internal Medicine|June 15, 2012
[Chronic kidney disease (CKD)--recent progress. Topics: VI. Chronic kidney disease (CKD) and associated disorders; 1. Chronic kidney disease and cardiovascular disease]Seiji Ueda, Sho-ichi Yamagishi, Nana Obara, et al.
Pageof 13

Showing results (1-10 of 124) with videos related to

Sort By:
Pageof 13
Hypertension Research : Official Journal of the Japanese Society of Hypertension|September 25, 2024
Correction: Urinary chloride-to-potassium ratio as a potential novel index for MR activity in patients with hypertensionHajime Nagasawa, Teruyuki Okuma, Seiji Ueda
Nihon Rinsho. Japanese Journal of Clinical Medicine|June 14, 2011
[Hyperfiltration]Yusuke Kaida, Seiji Ueda, Seiya Okuda
Hypertension Research : Official Journal of the Japanese Society of Hypertension|June 24, 2024
Urinary chloride-to-potassium ratio as a potential novel index for MR activity in patients with hypertensionHajime Nagasawa, Teruyuki Okuma, Seiji Ueda
Circulation Journal : Official Journal of the Japanese Circulation Society|February 5, 2014
Molecular mechanism underlying the renoprotective action of vitamin DYosuke Nakayama, Seiji Ueda, Seiya Okuda
Clinical and Experimental Nephrology|February 7, 2016
Accurate estimation of protein/creatinine ratio on urine sample in CKD patientsKensei Taguchi, Seiji Ueda, Kei Fukami
Current Pharmaceutical Design|September 28, 2007
Food-derived advanced glycation end products (AGEs): a novel therapeutic target for various disordersSho-ichi Yamagishi, Seiji Ueda, Seiya Okuda
Journal of Nephrology|March 30, 2010
New pathways to renal damage: role of ADMA in retarding renal disease progressionSeiji Ueda, Sho-Ichi Yamagishi, Seiya Okuda
Expert Opinion on Investigational Drugs|October 19, 2024
Dual blockade of endothelin A and angiotensin II type 1 receptors with sparsentan as a novel treatment strategy to alleviate IgA nephropathyHajime Nagasawa, Hitoshi Suzuki, Seiji Ueda, et al.
Current Pharmaceutical Design|May 14, 2008
Role of AGEs in diabetic nephropathyKei Fukami, Sho-Ichi Yamagishi, Seiji Ueda, et al.
Nihon Naika Gakkai Zasshi. the Journal of the Japanese Society of Internal Medicine|June 15, 2012
[Chronic kidney disease (CKD)--recent progress. Topics: VI. Chronic kidney disease (CKD) and associated disorders; 1. Chronic kidney disease and cardiovascular disease]Seiji Ueda, Sho-ichi Yamagishi, Nana Obara, et al.
Pageof 13